'''Ciclazindol''' ('''WY-23,409''') is an [[antidepressant]] and [[anorectic]] [[drug]] of the [[Tetracyclic antidepressant|tetracyclic]] [[chemical class]] that was developed in the mid to late 1970s, but was never marketed.<ref name="pmid96461">{{cite journal | vauthors = Ghose K, Rama Rao VA, Bailey J, Coppen A | title = Antidepressant activity and pharmacological interactions of ciclazindol | journal = Psychopharmacology | volume = 57 | issue = 1 | pages = 109–14 |date=April 1978 | pmid = 96461 | doi = 10.1007/BF00426966| url = }}</ref><ref name="pmid369921">{{cite journal | author = Levine S | title = A controlled comparative trial of a new antidepressant, ciclazindol | journal = The Journal of International Medical Research | volume = 7 | issue = 1 | pages = 1–6 | year = 1979 | pmid = 369921 | doi = | url = }}</ref> It acts as a [[norepinephrine reuptake inhibitor]], and to a lesser extent as a [[dopamine reuptake inhibitor]].<ref name="pmid96461"/><ref name="pmid106428">{{cite journal | vauthors = Oh VM, Ehsanullah RS, Leighton M, Kirby MJ | title = Influence of ciclazindol on monoamine uptake and CNS function in normal subjects | journal = Psychopharmacology | volume = 60 | issue = 2 | pages = 177–81 |date=January 1979 | pmid = 106428 | doi = 10.1007/BF00432290| url = }}</ref> Ciclazindol has no effects on the [[serotonin transporter|SERT]], [[serotonin receptor|5-HT receptor]]s, [[muscarinic acetylcholine receptor|mACh receptor]]s, or [[alpha-adrenergic receptor|α-adrenergic receptor]]s, and has only weak affinity for the [[H1 receptor|H<sub>1</sub> receptor]].<ref name="pmid106428"/><ref name="pmid507990">{{cite journal | vauthors = Waterfall JF, Smith MA, Gaston WH, Maher J, Warburton G | title = Cardiovascular and autonomic actions of ciclazindol and tricyclic antidepressants | journal = Archives Internationales de Pharmacodynamie et de Thérapie | volume = 240 | issue = 1 | pages = 116–36 |date=July 1979 | pmid = 507990 | doi = | url = }}</ref><ref name="pmid6244029">{{cite journal | vauthors = Gardner CR, Wilford AE | title = The effects of mianserine, amitriptyline, ciclazindol and viloxazine on presynaptic alpha-receptors in isolated rat atria [proceedings] | journal = [[British Journal of Pharmacology]] | volume = 68 | issue = 1 | pages = 184P–185P |date=January 1980 | pmid = 6244029 | pmc = 2044122 | doi = 10.1111/j.1476-5381.1980.tb10705.x }}</ref> As suggested by its [[local anesthetic]] properties,<ref name="pmid507990"/> ciclazindol may also inhibit [[sodium channel]]s. It is known to block [[potassium channel]]s as well.<ref name="pmid1504725">{{cite journal | vauthors = Noack T, Edwards G, Deitmer P | title = The involvement of potassium channels in the action of ciclazindol in rat portal vein | journal = British Journal of Pharmacology | volume = 106 | issue = 1 | pages = 17–24 |date=May 1992 | pmid = 1504725 | pmc = 1907450 | doi = 10.1111/j.1476-5381.1992.tb14286.x| url = |display-authors=etal}}</ref><ref name="pmid8609901">{{cite journal | vauthors = Lee K, Khan RN, Rowe IC | title = Ciclazindol inhibits ATP-sensitive K+ channels and stimulates insulin secretion in CR1-G1 insulin-secreting cells | journal = Molecular Pharmacology | volume = 49 | issue = 4 | pages = 715–20 |date=April 1996 | pmid = 8609901 | doi = | url = http://molpharm.aspetjournals.org/cgi/pmidlookup?view=long&pmid=8609901|display-authors=etal}}</ref>
